icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
See also
Décision d'accès précoce
14/11/2024
eNrlWF1v2jAUfedXoLw7CVCgTIFqY+2G1KqMFm3aS2WcC5gZO/UH0P36OQnd6JSoa6hfuhdk7Pjea/ucc68dne3WrL4Bqajgfa/hh14dOBEx5Yu+N729QKfe2aAWrfAGH3zW9UO/0fTqhGGl+l466s8Ac+V/u7r8CHY+SG9Qq0ditgKin3xnNGX+Z6yWVzhJv6lHG0Hj+hr0UsR9LzE6661HSksbxWAr5A+VYAJRsO85HF3dnRz2R0Fq7B+sGgXyEvNFoVHglWwSIyVwPcQaFkI+lMTbqmSbqgkoYSSBMdbLsRQbGkNc6GKOmYJKTubb+AbkhoFOnRQaD1ZkrSoZxyu8m8D9qDjo93Z0qHcahajRbXdarU6j0+51Tyu5kgdbVXwKdhFBctdqt8NetxcAD2IgNAU34qgZNk9Q2OyGQUwCBWsUG9QIkSBazCTkw7aLCMZgASgGxDBaYqMB2R8hqc46Fea2kQipbQNJmBuFYoQJAYUSaTlCHueqxDrHLJtnErqzGMoazKzxrCJaxqlf5ggnVA2fQt2RHwn3z+Ixpiph+MFfqaTqVmGJ7TBIK0juFpKu4FZaiWR2z/6yzw1jwQujnu4FzFHEqT4OheG6RMcuJlU3YigsL3blJ1pNevVuj0UK6vXM/hS8OO2MzYxRUlVkrQwaUHo6GZVr7NuWpw9YwVS606evlMdiq15f9w5x5ij67ExYodFExo27Zu+002i3K9P6uwV1SRY+N1IkEFhFpOoYoRvxuThW4ixPik09suQNEySrTgXBDErqU1RRfy0zHstpZ9xzx+t8oNDop/PbqoD9YkA+3GR/C03TuP8batWSk4uMZ+lRGvjLyZZrjpObi5HFWrbUOlHvgmC73fpLrHK++XP5H2S/gxLI3U3OSZ2V1515BnEU+iwvDV6Gmarcf64SO/Z2sZ+/v8UU+tDSwBFnkacJZ2I+On/9/PDnauEs7PETPXPnJrsGYG21yVUxaGbFleBRGcmeK7+QViCu53Na8rJWissoyF/1BrUoSF/0BrVfq6ayCg==
XBLmzbLebBasxNmV
Listen
